Novo Nordisk hires former Director General of DMA

Now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz will soon be spending his time at Novo Nordisk examining large amounts of data coming from the firm's clinical trials.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

When the now-former Director General of the Danish Medicines Agency (DMA) Thomas Senderovitz steps into his new role at Novo Nordisk in May, his main focus area will be clinical development, according to an email sent from Novo Nordisk to MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading